报价延迟最少15分钟:2026/01/10 16:34 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.25 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-33.87/-129.50
|
|
企业价值
13.74M
|
| 资产负债 |
|
每股账面净值
5.30
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options. |
